Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

By R. Sterling, E. Lissen, N. Clumeck, R. Solá, Mendes Cassia Correa, J. Montaner, Mark S Sulkowski, F. Torriani, D. Dieterich, David L. Thomas and 2 more. Hepatology, 2006

4,602 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/432188c216e44c16527ef96694cd41b8ae2ce146

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. C. Day
2. Q. Anstee
3. Asociacion Latinoamericana para el Estudio del Higado
4. L. Adams
5. Vincent Wai-Sun Wong
6. Z. Younossi
7. G. Targher

In Hepatology

1. C. Day
2. Asociacion Latinoamericana para el Estudio del Higado
3. M. H. Murad
4. Q. Anstee

Citations in the corpus

• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015, methodology): “time of liver biopsy or within 6-months were used to calculate the FIB-4 and Non-alcoholic fatty liver fibrosis scores (NAFLD fibrosis score) as previously described [27–29].”
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Among the different serum biomarkers studied in NAFLD, only NFS and FIB-4 have been externally validated more than once, in different NAFLD populations and with consistent results [119].”
• Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis (2017, methodology): “Dozens of noninvasive models composed of blood biochemical biomarkers have been proposed to detect LF, including aspartate aminotransferase to platelets ratio index (APRI)((5)) and fibrosis-4 index (FIB-4).((6)) However, APRI and FIB-4 were established based on patients with hepatitis C virus (HCV) ”
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “Among 14 serum-based biomarker panels for hepatic fibrosis, the FibroTest,(247-249) the serum AST/platelet ratio index (APRI),(250) the Fibrosis-4 index (FIB-4),(251,252) and the enhanced liver fibrosis test(253,254) have emerged as the better candidates in AIH.”
• The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease (2020, background): “Monitoring of fibrosis progression in the clinic might rely on a combination of noninvasive scores (NFS, FIB-4 and ADAPT) and LSM [263, 264] although this strategy requires further validation.”